CDK4/6 inhibitors in advanced breast cancer, what is beyond?

Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2-...

Full description

Saved in:
Bibliographic Details
Main Authors: Amrallah A. Mohammed (Author), Hanaa Rashied (Author), Fifi Mostafa Elsayed (Author)
Format: Book
Published: Frontiers Media S.A., 2019-07-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_0b9201e0cdba4c36892bca9c726d1cb8
042 |a dc 
100 1 0 |a Amrallah A. Mohammed  |e author 
700 1 0 |a Hanaa Rashied  |e author 
700 1 0 |a Fifi Mostafa Elsayed  |e author 
245 0 0 |a CDK4/6 inhibitors in advanced breast cancer, what is beyond? 
260 |b Frontiers Media S.A.,   |c 2019-07-01T00:00:00Z. 
500 |a 10.4081/oncol.2019.416 
500 |a 1970-5557 
500 |a 1970-5565 
520 |a Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/6I) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2- ABC, mechanisms of resistance, and promising future implementation. 
546 |a EN 
690 |a Breast cancer 
690 |a CDK4/6 inhibitors 
690 |a predictors of response and resistance. 
690 |a Other systems of medicine 
690 |a RZ201-999 
690 |a Internal medicine 
690 |a RC31-1245 
655 7 |a article  |2 local 
786 0 |n Oncology Reviews, Vol 13, Iss 2 (2019) 
787 0 |n https://www.oncologyreviews.org/index.php/or/article/view/416 
787 0 |n https://doaj.org/toc/1970-5557 
787 0 |n https://doaj.org/toc/1970-5565 
856 4 1 |u https://doaj.org/article/0b9201e0cdba4c36892bca9c726d1cb8  |z Connect to this object online.